Walleye Trading
BMY.RT

Walleye Trading’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Walleye Trading’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-249,100
Closed -$560K – 5179
2020
Q3 		$560K Sell
249,100
-4,000
-2% -$11.4K ﹤0.01% 2154
2020
Q2 		$906K Sell
253,100
-107,100
-30% -$386K 0.01% 1747
2020
Q1 		$1.37M Sell
360,200
-440,200
-55% -$1.45M 0.01% 1093
2019
Q4 		$2.41M Buy
+800,400
New +$2.08M 0.02% 1067

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Walleye Trading's BMY.RT Position: Q1 2021 in Review

Walleye Trading sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 245,900 shares — an estimated $170K sold.

Walleye Trading first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.66M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Walleye Trading reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Walleye Trading sold 245,900 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $170K.
  • Walleye Trading first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Walleye Trading's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.66M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Walleye Trading's 13F filing for Q1 2021, filed 17 May 2021.